In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
HOME > BUSINESS
BUSINESS
- Towa, Sawai See Continued Growth in Japan in FY2024 amid New WPP Strategies
May 20, 2024
- Pfizer Rolls Out Single-Dose Version of COVID-19 Vaccine in Japan
May 20, 2024
- Keytruda Gets Nod for Gastric, Biliary Tract Cancer in Japan
May 20, 2024
- Prevymis Now Approved for CMV Prevention in Organ Transplant Recipients in Japan
May 20, 2024
- Braftovi-Mektovi Combo Broadens Label to Thyroid Cancer: Ono
May 20, 2024
- Amylyx Pulls Out from Japan after ALS Trial Flop
May 20, 2024
- Mitsubishi Tanabe’s Earnings Sink 2-Digits in FY2023 on Backlash from Previous Gilenya Royalties
May 17, 2024
- Eisai to Appoint CEO’s Son for Representative Post in Prelude to Succession
May 17, 2024
- Ultragenyx’s Evkeeza Gets Label Update to Allow Use under Age 5
May 17, 2024
- No Clenafin Generic Competition until June 2025: Kaken
May 17, 2024
- Japan Generic Market Set to Surpass 1.6 Trillion Yen by 2032: Fuji Keizai
May 17, 2024
- Xocova Forerunner in March GP Rep Promotion Rankings: Intage
May 17, 2024
- Eisai Begins Rolling Submission for Subcutaneous Leqembi in US
May 16, 2024
- Eisai Sees Global Sales of Leqembi Surging to 56.5 Billion Yen in FY2024
May 16, 2024
- Mounjaro Going Back to Normal Supply from June: Lilly/Mitsubishi
May 16, 2024
- Amgen Files BiTE Drug Tarlatamab for Lung Cancer in Japan
May 16, 2024
- As Latuda Sales Evaporate, Sumitomo Shakes Up Top Brass for Turnaround
May 15, 2024
- Teva to Let Go of Japan Generic Business in 2025 but Denies Full Exit
May 15, 2024
- Sanofi Files Sarclisa as 1st-Line Quad Therapy for MM in Japan
May 15, 2024
- Seikagaku’s Herniated Disk Drug Accepted for US FDA Review
May 15, 2024
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…